Patents by Inventor Mark Henney

Mark Henney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11730917
    Abstract: Gamma brain stimulation for preventing or treating Alzheimer's disease or sleeping disorders using light or sound is known. A strobing 40 Hz light source has been shown to cause positive effects due to the stimulation. It is an advantage to know the actual dosage of light that enters the person's eyes in order to understand the relationship between dosage and effectiveness. A camera is used to detect the subject's gaze angle, distance, pupil diameter and any other factors that affect the light power that enters the eye. A target dosage is first determined by a medical worker, such as to determine the effects of the exact same dosage on a group of similar persons, such as Alzheimer's patients. With deviations of gaze angle, distance, and pupil size from the ideal, the effective dosage is decreased. The disclosed system adjusts the actual dosage, such as session duration, based on such factors so that the final dosage received by the person is consistent and meets the target dosage.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 22, 2023
    Assignee: Optoceutics ApS
    Inventors: Marcus Carstensen, Paul Michael Petersen, Jes Broeng, Mark Henney, Ngoc Mai Nguyen, Robert Dobkin
  • Publication number: 20220134047
    Abstract: Gamma brain stimulation for preventing or treating Alzheimer's disease or sleeping disorders using light or sound is known. A strobing 40 Hz light source has been shown to cause positive effects due to the stimulation. It is an advantage to know the actual dosage of light that enters the person's eyes in order to understand the relationship between dosage and effectiveness. A camera is used to detect the subject's gaze angle, distance, pupil diameter and any other factors that affect the light power that enters the eye. A target dosage is first determined by a medical worker, such as to determine the effects of the exact same dosage on a group persons, such as Alzheimer's patients. With deviations of gaze angle, distance, and pupil size from the ideal, the effective dosage is decreased. The disclosed system adjusts the actual dosage, such as session duration, based on such factors so that the final dosage received by the person is consistent and meets the target dosage.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 5, 2022
    Inventors: Marcus Carstensen, Paul Michael Petersen, Jes Broeng, Mark Henney, Ngoc Mai Nguyen, Robert Dobkin